Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8

Omar Dabbous; Benit Maru; Jeroen P Jansen; Maria Lorenzi; Martin Cloutier; Annie Guérin; Irina Pivneva; Eric Q Wu; Ramesh Arjunji; Douglas Feltner; Douglas M Sproule

doi:10.1007/s12325-019-01088-0

Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8

Adv Ther. 2019 Nov;36(11):2982-2985. doi: 10.1007/s12325-019-01088-0. Epub 2019 Sep 11.

Authors

Affiliations

¹ AveXis, Inc, Bannockburn, IL, USA.
² Precision Xtract, Oakland, CA, USA.
³ Analysis Group, Inc, Montreal, QC, Canada.
⁴ Analysis Group, Inc, Boston, MA, USA.
⁵ AveXis, Inc, Bannockburn, IL, USA. [email protected].

No abstract available

Keywords: AVXS-101; Indirect treatment comparison; Neuroscience; Nusinersen; Onasemnogene abeparvovec; Spinal muscular atrophy type 1 (SMA type 1).

Publication types

Letter
Comment

MeSH terms

Humans
Infant
Muscular Atrophy, Spinal*
Oligonucleotides*

Substances

Oligonucleotides
nusinersen